Breast implant‐associated, ALK‐negative, T‐cell, anaplastic, large‐cell lymphoma: Establishment and characterization of a model cell line (TLBR‐1) for this newly emerging clinical entity
Open Access
- 8 November 2010
- Vol. 117 (7), 1478-1489
- https://doi.org/10.1002/cncr.25654
Abstract
BACKGROUND: Primary lymphomas of the breast are very rare (0.2‐1.5% of breast malignancies) and the vast majority (95%) are of B‐cell origin. Recently, 40 cases of clinically indolent anaplastic large‐cell kinase (ALK)‐negative, T‐cell, anaplastic, non‐Hodgkin lymphomas (T‐ALCL) have been reported worldwide. METHODS: A tumor biopsy specimen from a patient in this series was obtained for characterization. By using a human stromal feeder layer and IL‐2, a novel cell line, TLBR‐1, was established from this biopsy and investigated by using cytogenetics and various biomolecular methods. RESULTS: Immunoperoxidase staining of the tumor biopsy showed a CD30/CD8/CD4 coexpressing T‐cell population that was epithelial membrane antigen (EMA)+ and perforin+. Multiplex polymerase chain reaction (PCR) of TCRγ genes showed monoclonality that suggested a T‐cell origin, yet pan‐T markers CD2/5/7, anaplastic large‐cell kinase (ALK)‐1, pancytokeratins, CD20, CD56, and Epstein‐Barr virus (EBV) by in situ hybridization (ISH) were negative. TLBR‐1 is IL‐2 dependent, has a relatively long doubling time (55 hours), and displays different cellular shapes in culture. Cytogenetic analysis of tumor and TLBR‐1 cells confirmed a highly anaplastic cell population with a modal number of 47 chromosomes lacking t(2;5). PCR screens for EBV and human T‐lymphotropic virus types 1 and 2 (HTLV‐1/2) were negative. Fluorescence‐activated cell‐sorting (FACS) analysis showed strong positivity for CD4/8, CD30, CD71, and CD26 expression, and antigen presentation (HLA‐DR+CD80+CD86+), IL‐2 signaling (CD25+CD122+), and NK (CD56+) markers, and Western blots demonstrated strong Notch1 expression. Severe combined immunodeficiency (SCID) mouse TLBR‐1 heterotransplants recapitulated the histology and marker characteristics of the original tumor. CONCLUSIONS: TLBR‐1, a novel ALK‐negative, T‐cell, anaplastic, large‐cell lymphoma, closely resembles the original biopsy and represents an important tool for studying this newly recognized disease entity. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapyHaematologica, 2009
- Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentationDiagnostic Pathology, 2009
- Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorderLaboratory Investigation, 2008
- CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulatorsJournal of Cutaneous Pathology, 2006
- Primary Cutaneous T-Cell LymphomasHematology-American Society Hematology Education Program, 2006
- Immunophenotypic Analysis of Anaplastic Large Cell Lymphoma by Flow CytometryAmerican Journal of Clinical Pathology, 2003
- Immunophenotypic Analysis of Anaplastic Large Cell Lymphoma by Flow CytometryAmerican Journal of Clinical Pathology, 2003
- Notch Signaling in CancerCancer Biology & Therapy, 2002
- The ultrastructural and immunohistochemical heterogeneity of CD-30-positive neoplasms: so-called anaplastic large cell Ki-1 lymphomasMedical Molecular Morphology, 2001
- PCR Analysis of Immunoglobulin Heavy Chain (IgH) and TcR-γ Chain Gene Rearrangements in the Diagnosis of Lymphoproliferative Disorders: Results of a Study of 525 CasesLaboratory Investigation, 2000